Ju 14-16, 2009 - Sa Dig Mari Hl

Supement- Sake Bios

Dr. Mark Benedyk, Head, The Pfzer Incubator

Dr. Mark Benedyk is Head o The Pzer Incubator LLC, a company created by Pzer to oer scientist-entrepreneurs anopportunity to bring their medical innovations to patients.Prior to joining The Pzer Incubator, Dr. Benedyk was Vice President o Business Development at Ascenta Therapeutics, aclinical-stage company developing pro-apoptotic small molecule drugs or the treatment o cancer. There he led contractand licensing negotiations or Ascenta, and was part o the executive team that secured $50 million or Ascenta’s Series Cnancing.Beore coming to Ascenta, Dr. Benedyk was Vice President o Business Development and Director o OptimerBiotechnology, an international biotechnology subsidiary o Optimer Pharmaceuticals, with operations in the U.S., Singaporeand Taiwan. At Optimer he led business development activities or Optimer Biotechnology in Singapore, and was part o the executive team that raised $22 million or the Series C&D nancing rounds or Optimer prior to its successul IPO inFebruary o 2007.Previously, Dr. Benedyk has held business development positions at rila bioconsulting, Farmal Biomedicines, AuroraBiosciences (now Vertex Pharmaceuticals), lan Pharmaceuticals, and Argonex Corporation. During his tenure in thepharmaceutical and biotechnology industries, Dr. Benedyk has personally led transactions worth over $300 million andparticipated in over $500 million worth o product licensing, corporate acquisition and undraising transactions. Dr. Benedykreceived his Ph.D. in Genetics and Developmental Biology rom The Rockeeller University, where he was a Lucille P. MarkeyGraduate Fellow. He received his B.S. in Microbiology and Botany rom the University o Michigan.

G. Steven Burrill, CEO, Burrill & Company

G. Steven Burrill has been involved in the growth and prosperity o the biotechnology industry or over 40 years. An earlypioneer, Mr. Burrill is one o the original architects o the industry and one o its most avid and sustained developers.He currently serves as Chairman o the Boards o Pharmasset (NASDAQ: VRUS), BioImagene and NewBridge, and is amember o the Boards o Directors o Catalyst Biosciences, CrossCart, DepoMed (NASDAQ: DEPO), Ikano Therapeutics,Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to ounding Burrill & Company in 1994,he spent 28 years with Ernst & Young, directing and coordinating the rm’s services to clients in the biotechnology/liesciences/high technology/manuacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investmentvisionary by the prestigious Scientic American magazine (The Scientic American 50), and in 2008, he received the BayBioPantheon 2008 DiNA lietime achievement award or his worldwide biotech leadership.

Peter Beattie, Former Queensland Premier

The Honourable Peter Beattie is Queensland’s Trade and Investment Commissioner or the Americas. He was Premier(Governor) o the state o Queensland rom June 1998 to September 2007, when he retired and handed over to his deputy. As Premier his key strategy was to turn Queensland into Australia’s Smart State by reocusing the education system, skillingthe workorce, encouraging research and development and creating thousands o long-term, new-age jobs in high techindustries such as biotechnology, inormation technology and aviation. Ater working as a lawyer, Mr. Beattie was elected to State Parliament as the Member or Brisbane Central in 1989. He wasimmediately appointed as the chairman o the reorming Parliamentary Criminal Justice Committee. From July 1995 heserved as Minister or Health beore becoming Leader o the Opposition in February 1996.

Peter BeattieDr. Mark BenedykG. Steven Burrill

Kay Chandler, Partner, Cooley Godward

Kay Chandler is a partner in Cooley Godward Kronish’s Business department and an active member o the Firm’s LieSciences practice group.Ms. Chandler specializes in representing public and private lie sciences companies in a wide range o securities, corporateand commercial matters that are critical to their businesses. She advises clients on all aspects o securities and corporatematters, including private nancings, public oerings, mergers and acquisitions, and corporate governance and disclosureissues. She regularly counsels companies on complex commercial transactions, including technology licenses andacquisitions, research and development collaborations, supply, distribution and manuacturing agreements, and prot-sharing and co-promotion arrangements, based on her extensive experience in assisting clients to establish and maintainrelationships with pharmaceutical, medical device, chemical and agricultural companies in the United States, Europe and Asia. She works closely with her clients to understand each client’s business and strategic objectives and to structure andnegotiate transactions to meet those objectives.

Kay Chandler

Nancy T. Chang, Ph.D., Chairman and Sr. Managing Director or Asia at OrbiMed Healthcare Fund Management.

Nancy T. Chang, Ph.D. is currently Chairman and Sr. Managing Director or Asia at OrbiMed Healthcare FundManagement. Dr. Chang was Co-Founder o Tanox, a biotech and pharmaceutical company in Houston, andserved as Chairman, CEO and President at dierent times rom 1986-2007 . From 1982 to 1986, Dr. Chang served asDirector o Research at Centocor, Inc. From 1986 to 1991, she was Associate Proessor o Virology at Baylor Collegeo Medicine. Dr. Chang serves on the Boards o Project Hope, Charles River Laboratories and a number o privatebiotechnology companies. Dr. Chang received a Ph.D. in biological chemistry rom Harvard University.

Jonghoon Choi, Executive director, Korea Biotechnology Industry Organization

Dr. Jonghoon Choi, has been working or Korea Biotechnology Industry Organization since early 2008 as an executivedirector. Beore joining Korea BIO he served a director o business development at LG Lie Sciences rom 2004 orour years. And rom 2002 to 2004 he worked or strategic planning and marketing department at Korea Instituteo Toxicology. Dr. Choi, received a MS and Ph.D. in the eld o toxicology rom Miami University and worked as apostdoctoral research ellow at North Carolina State University.

Nancy ChangJonghoon ChoiSang Chul KimHoon Y. Chung

Sang Chul Kim, Director General, KOTRA – Los Angeles

Mr. Sang Chul Kim has been working or KOTRA (Korea Trade-Investment Promotion Agency) since 1983. Since joining KOTRA, he has worked in six dierent oces o KOTRA. During his early years, he has worked in Kuala Lumpur, Tokyo and Tripoli beore becoming a team leader o Asia Pacic team at KOTRA headquarter. He was also the DirectorGeneral at KOTRA’s Budapest oce. He is also the author o ‘25 O’clock, Eastern Europe’. Mr.Kim has been servingthe Los Angeles area since 2007 and have been building relationships in the Biotechnology industry including Biocom.

Hoon Y. Chung, Founder and President, MedExGen Inc.

Hoon Y. Chung, M.D., Ph.D. is a ounder and president/CEO o MedExGen Inc, a spin-o lie sciences company atHanyang University, Seoul, Korea. Ater his graduation o Medical school he was working as a clinician in KEPCOhospital, Seoul, Korea or 3 years. He was a research ellow in Sloan-Kettering Institute in New York or 2 years. He hasserved as a board o directors o Korean Microbiology Association, and Korean Society o Immunology or 15 years. And he also served as a chie executive o Korean Society o Immunology or 4 years. Prior to ounding MedExGen Inc,Hoon has been a Proessor o Medical Microbiology and Immunology in Hanyang University or 23 years. During thisperiod o time he published more than 50 papers in the elds o Medical Microbiology and Immunology and has alsoobtained more than 25 patents through out the world in the eld o therapeutic protein innovations.

Peter J. Claude, Advisory Partner, PricewaterhouseCoopers

Peter Claude is a Partner in the San Francisco, CA oce o PricewaterhouseCoopers, where he leads our practiceserving West Coast pharmaceutical and lie science advisory clients. Peter brings an in-depth knowledge o thepharmaceutical and lie sciences industry to his extensive process and controls background as well as an internationalperspective rom a our-year tour o duty in Switzerland. Peter’s clients have included a broad range o large and smalldomestic and multinational pharmaceutical, biotechnology and medical device manuacturers as well as pharmacybenet managers. His engagements have covered corporate, commercial and R&D compliance issues, channelstrategy and commercial contracting and perormance improvement, pharmacy benet manager and wholesalerrelationships, government price reporting, and strategic alliances.Peter was the principal author o “Recapturing the Vision”, PwC’s groundbreaking study on improving thePharmaceutical Industry’s reputation, and o two published studies on compliance issues in the Medical Device Industry.Peter has spoken at a number o pharmaceutical and medical device industry events on industry and compliance andrelated process improvement topics.

Peter J. Claude